MG 98

Drug Profile

MG 98

Alternative Names: HYB 101584; MG-98

Latest Information Update: 20 Mar 2008

Price : $50

At a glance

  • Originator MethylGene
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Head and neck cancer; Myelodysplastic syndromes; Renal cancer; Solid tumours

Most Recent Events

  • 20 Mar 2008 Discontinued - Phase-I for Solid tumours in United Kingdom (Injection)
  • 20 Mar 2008 Discontinued - Phase-II for Renal cancer in USA (Injection)
  • 20 Mar 2008 Discontinued - Phase-II for Renal cancer in Canada (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top